Bayer Inks $1.3B Agreement with Kumquat to Develop Breakthrough KRAS Cancer Drug

San Diego, CA and Berlin, August 12, 2025 (Reuters) -- Bayer has signed a deal worth up to $1.3 billion with Kumquat Biosciences to develop a KRAS G12D inhibitor for cancers with few effective treatments. Kumquat will manage the initial trial phase, while Bayer will handle later development and commercialization. The agreement enhances Bayer’s precision oncology portfolio and provides Kumquat with resources to advance its broader pipeline.

Read full article here.